Elipse Balloon Multi-Center Study Published
We are pleased to announce the publication of our European multi-center trial results in Endoscopy! Thank you to our European investigators and patients who participated in a groundbreaking study on the Elipse Balloon.
Obesity is Complex. Why Aren’t its Treatments?
In a recent article on MedCityNews, Dr. Shantanu Gaur and Michael Fergusson (CEO of Ayogo) explore the next generation of more personalized obesity treatments. Click here for the article.
Allurion Named Finalist in Lyfebulb-Novo Nordisk Innovation Summit
We were honored to be finalists at the Lyfebulb – Novo Nordisk Innovation Summit. Here is a video of our founder, Dr. Shantanu Gaur, presenting the Elipse Balloon to a packed crowd!
Allurion Technologies’ Elipse Intragastric Balloon Receives Prestigious SAGES Innovation Award
Allurion Technologies announced today that its flagship product, the Elipse Balloon, has received the prestigious Emerging Technology Innovation Award from the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES). The Elipse Device is the world’s first procedureless™ intragastric balloon: it is placed and removed without surgery, endoscopy or anesthesia. It is the first intragastric balloon to receive this award. The Elipse System received European Union CE marking in late 2015 and is now available at leading weight loss centers in the United Kingdom, Italy and France. Plans for commercial expansion within Europe and in the Middle East are underway. For the…
Why have healthcare companies and physicians failed to solve the obesity epidemic?
In a recent guest post on MedCity News, Dr. Shantanu Gaur asks why healthcare companies and physicians have failed to solve the obesity epidemic. The answer has much more to do with how we treat the consumer than how we think about technology. Check out the article here!
Three Things The Tech Industry Has Right And The Medical Industry Has Wrong
Dr. Shantanu Gaur recently authored a guest post on TechCrunch on what the medtech industry can learn from the tech industry. Namely, 1) be open with data; 2) create an experience, not just a product; and 3) treat users as participants, not just purchasers. Check out the article here!
Elipse System Receives European Marketing Approval
Today, we are happy to announce that the Elipse System has received European marketing approval! The Elipse Balloon is now available for sale in select centers in Europe. Please read the press release for more details.
Two Gastric Balloons Approved By FDA
In a landmark month for obesity devices, the ReShape Integrated Dual Balloon System and the Orbera Gastric Balloon were both approved by the US FDA for use in obese individuals. While the approval of these two balloons represents a critical step forward for the treatment of obesity in the United States, the devil may be in the details. But first, the good stuff: both balloons have been shown to lead to more weight loss than just dieting in large, well-designed clinical trials. Moreover, participants in the ReShape FDA study who were followed for 6 months after their balloons were removed…
Team Allurion at IFSO 2015
Team Allurion gave a podium presentation at IFSO 2015, hosted its 1st Expert Meeting, and engaged with future Elipse users from all around the world. Thank you to the organizers for a wonderful conference!
Do consumers want weight loss surgery?
Market researchers from Treato recently mined online conversations from around the web to understand consumer sentiment on weight loss surgery. Interestingly, they concluded that 85% of respondents who consider themselves at least 30lbs overweight would not choose weight loss surgery for themselves. These results mirror those from previous studies on consumer preference that concluded that most patients eligible for weight loss surgery would not prefer it. These results highlight an important theme for the overweight and obese market: most consumers do not want weight loss surgery. Several non-surgical options are under development (including gastric balloons) to provide consumers with safe and…